Knight Days Sales Outstanding vs Pb Ratio Analysis

GUD Stock

CAD 5.29 0.01 0.19%

Knight Therapeutics financial indicator trend analysis is infinitely more than just investigating Knight Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Knight Therapeutics is a good investment. Please check the relationship between Knight Therapeutics Days Sales Outstanding and its Pb Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Days Sales Outstanding vs Pb Ratio

Days Sales Outstanding vs Pb Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Knight Therapeutics Days Sales Outstanding account and Pb Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Knight Therapeutics' Days Sales Outstanding and Pb Ratio is -0.24. Overlapping area represents the amount of variation of Days Sales Outstanding that can explain the historical movement of Pb Ratio in the same time period over historical financial statements of Knight Therapeutics, assuming nothing else is changed. The correlation between historical values of Knight Therapeutics' Days Sales Outstanding and Pb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Sales Outstanding of Knight Therapeutics are associated (or correlated) with its Pb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pb Ratio has no effect on the direction of Days Sales Outstanding i.e., Knight Therapeutics' Days Sales Outstanding and Pb Ratio go up and down completely randomly.

Correlation Coefficient

-0.24

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Days Sales Outstanding

Pb Ratio

Most indicators from Knight Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Knight Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Knight Therapeutics' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 23rd of November 2024, Enterprise Value Multiple is likely to grow to 14.58, while Selling General Administrative is likely to drop about 23.9 M.

	2021	2022	2023	2024 (projected)
Interest Expense	3.6M	6.6M	12.5M	9.4M
Depreciation And Amortization	47.9M	62.6M	50.4M	52.9M

Interest Expense Depreciation And Amortization

Knight Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Total Current Assets	Common Stock	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Good Will	Short Term Investments	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Short Term Debt	Intangible Assets	Non Current Liabilities Total
Total Assets		0.96	-0.37	0.51	0.63	0.94	0.87	0.98	0.4	0.61	0.64	0.44	0.34	0.59	0.79	-0.08	0.68	0.93	0.37	0.6	0.44	0.84	0.64	0.63	0.57	0.54
Total Stockholder Equity	0.96		-0.53	0.65	0.75	0.93	0.92	0.99	0.18	0.37	0.46	0.22	0.55	0.43	0.66	-0.21	0.49	0.93	0.47	0.44	0.22	0.76	0.41	0.46	0.44	0.42
Net Debt	-0.37	-0.53		-0.99	-0.93	-0.4	-0.73	-0.53	0.06	0.25	0.33	0.09	-0.38	0.46	0.22	0.19	0.33	-0.4	-0.62	0.45	0.13	0.08	0.32	0.16	0.4	0.46
Cash	0.51	0.65	-0.99		0.95	0.52	0.82	0.65	0.01	-0.12	-0.19	-0.01	0.39	-0.3	-0.07	-0.19	-0.17	0.51	0.6	-0.3	-0.05	0.07	-0.17	-0.03	-0.26	-0.31
Cash And Short Term Investments	0.63	0.75	-0.93	0.95		0.66	0.9	0.75	0.12	-0.01	-0.12	0.08	0.44	-0.23	0.05	-0.2	-0.08	0.65	0.78	-0.23	0.06	0.19	-0.06	0.06	-0.21	-0.24
Common Stock Shares Outstanding	0.94	0.93	-0.4	0.52	0.66		0.85	0.95	0.33	0.5	0.54	0.39	0.47	0.46	0.71	-0.12	0.55	0.94	0.51	0.48	0.37	0.78	0.51	0.59	0.45	0.42
Total Current Assets	0.87	0.92	-0.73	0.82	0.9	0.85		0.93	0.3	0.31	0.21	0.27	0.4	0.17	0.38	-0.25	0.27	0.83	0.66	0.18	0.3	0.49	0.28	0.35	0.11	0.16
Common Stock	0.98	0.99	-0.53	0.65	0.75	0.95	0.93		0.27	0.45	0.49	0.32	0.48	0.44	0.67	-0.16	0.52	0.93	0.48	0.45	0.31	0.75	0.47	0.52	0.44	0.41
Other Current Liab	0.4	0.18	0.06	0.01	0.12	0.33	0.3	0.27		0.86	0.47	0.91	-0.64	0.34	0.38	0.37	0.51	0.26	0.19	0.31	0.97	0.22	0.75	0.6	0.2	0.16
Total Current Liabilities	0.61	0.37	0.25	-0.12	-0.01	0.5	0.31	0.45	0.86		0.83	0.89	-0.45	0.74	0.76	0.37	0.86	0.45	-0.06	0.72	0.9	0.61	0.98	0.85	0.63	0.59
Property Plant And Equipment Net	0.64	0.46	0.33	-0.19	-0.12	0.54	0.21	0.49	0.47	0.83		0.66	-0.1	0.85	0.93	0.39	0.93	0.5	-0.31	0.87	0.55	0.81	0.89	0.89	0.89	0.75
Current Deferred Revenue	0.44	0.22	0.09	-0.01	0.08	0.39	0.27	0.32	0.91	0.89	0.66		-0.55	0.37	0.49	0.54	0.59	0.28	0.07	0.38	0.9	0.3	0.79	0.82	0.31	0.19
Retained Earnings	0.34	0.55	-0.38	0.39	0.44	0.47	0.4	0.48	-0.64	-0.45	-0.1	-0.55		-0.05	0.15	-0.43	-0.14	0.46	0.37	-0.01	-0.61	0.34	-0.36	-0.17	0.09	0.08
Accounts Payable	0.59	0.43	0.46	-0.3	-0.23	0.46	0.17	0.44	0.34	0.74	0.85	0.37	-0.05		0.89	0.04	0.93	0.48	-0.37	0.99	0.45	0.84	0.84	0.64	0.91	0.97
Non Current Assets Total	0.79	0.66	0.22	-0.07	0.05	0.71	0.38	0.67	0.38	0.76	0.93	0.49	0.15	0.89		0.15	0.93	0.7	-0.12	0.9	0.47	0.95	0.85	0.76	0.93	0.83
Non Currrent Assets Other	-0.08	-0.21	0.19	-0.19	-0.2	-0.12	-0.25	-0.16	0.37	0.37	0.39	0.54	-0.43	0.04	0.15		0.23	-0.23	-0.24	0.0	0.23	-0.08	0.32	0.4	0.19	-0.15
Net Receivables	0.68	0.49	0.33	-0.17	-0.08	0.55	0.27	0.52	0.51	0.86	0.93	0.59	-0.14	0.93	0.93	0.23		0.55	-0.25	0.92	0.6	0.87	0.95	0.82	0.89	0.85
Good Will	0.93	0.93	-0.4	0.51	0.65	0.94	0.83	0.93	0.26	0.45	0.5	0.28	0.46	0.48	0.7	-0.23	0.55		0.45	0.49	0.31	0.79	0.49	0.48	0.48	0.46
Short Term Investments	0.37	0.47	-0.62	0.6	0.78	0.51	0.66	0.48	0.19	-0.06	-0.31	0.07	0.37	-0.37	-0.12	-0.24	-0.25	0.45		-0.38	0.11	-0.02	-0.16	-0.05	-0.44	-0.37
Inventory	0.6	0.44	0.45	-0.3	-0.23	0.48	0.18	0.45	0.31	0.72	0.87	0.38	-0.01	0.99	0.9	0.0	0.92	0.49	-0.38		0.44	0.85	0.83	0.68	0.91	0.97
Other Current Assets	0.44	0.22	0.13	-0.05	0.06	0.37	0.3	0.31	0.97	0.9	0.55	0.9	-0.61	0.45	0.47	0.23	0.6	0.31	0.11	0.44		0.33	0.82	0.66	0.3	0.31
Other Stockholder Equity	0.84	0.76	0.08	0.07	0.19	0.78	0.49	0.75	0.22	0.61	0.81	0.3	0.34	0.84	0.95	-0.08	0.87	0.79	-0.02	0.85	0.33		0.73	0.65	0.88	0.83
Total Liab	0.64	0.41	0.32	-0.17	-0.06	0.51	0.28	0.47	0.75	0.98	0.89	0.79	-0.36	0.84	0.85	0.32	0.95	0.49	-0.16	0.83	0.82	0.73		0.84	0.76	0.72
Short Term Debt	0.63	0.46	0.16	-0.03	0.06	0.59	0.35	0.52	0.6	0.85	0.89	0.82	-0.17	0.64	0.76	0.4	0.82	0.48	-0.05	0.68	0.66	0.65	0.84		0.6	0.54
Intangible Assets	0.57	0.44	0.4	-0.26	-0.21	0.45	0.11	0.44	0.2	0.63	0.89	0.31	0.09	0.91	0.93	0.19	0.89	0.48	-0.44	0.91	0.3	0.88	0.76	0.6		0.86
Non Current Liabilities Total	0.54	0.42	0.46	-0.31	-0.24	0.42	0.16	0.41	0.16	0.59	0.75	0.19	0.08	0.97	0.83	-0.15	0.85	0.46	-0.37	0.97	0.31	0.83	0.72	0.54	0.86

Click cells to compare fundamentals

Knight Therapeutics Account Relationship Matchups

Knight Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.0B	991.9M	1.1B	945.5M	952.1M
Total Stockholder Equity	810.7M	886.2M	842.0M	825.9M	746.9M	823.4M
Net Debt	(107.1M)	(173.4M)	(45.0M)	6.0M	10.3M	10.8M
Cash	169.3M	229.6M	86.0M	71.7M	58.8M	55.8M
Cash And Short Term Investments	430.6M	411.3M	163.0M	191.2M	154.4M	146.7M
Common Stock Shares Outstanding	140.1M	132.0M	124.5M	114.9M	107.5M	123.8M
Liabilities And Stockholders Equity	1.3B	1.0B	991.9M	1.1B	945.5M	952.1M
Total Current Assets	698.2M	554.6M	307.3M	395.6M	365.1M	556.5M
Common Stock	723.8M	694.4M	628.9M	599.1M	540.0M	625.0M
Other Current Liab	185.8M	1.3M	2.0M	15.0M	7.9M	7.5M
Total Current Liabilities	350.8M	114.1M	105.3M	141.3M	114.0M	96.9M
Property Plant And Equipment Net	29.0M	26.2M	29.9M	22.6M	17.9M	14.0M
Current Deferred Revenue	39.9M	14.6M	9.7M	1.2M	1.4M	1.3M
Retained Earnings	52.2M	174.5M	191.6M	161.8M	150.9M	178.6M
Accounts Payable	72.8M	44.5M	65.3M	106.1M	85.4M	89.6M
Non Current Assets Total	607.1M	485.0M	684.6M	659.2M	580.4M	435.2M
Non Currrent Assets Other	52.7M	47.3M	47.9M	48.2M	7.8M	7.4M
Net Receivables	111.7M	82.0M	67.4M	110.2M	98.2M	55.5M
Short Term Investments	261.3M	181.7M	77.0M	119.5M	95.7M	172.8M
Inventory	70.9M	56.5M	72.4M	92.5M	91.8M	96.4M
Other Current Assets	85.0M	4.8M	4.5M	1.7M	20.6M	13.2M
Other Stockholder Equity	17.2M	18.8M	21.9M	23.8M	26.0M	17.1M
Total Liab	390.2M	153.4M	149.9M	229.0M	198.6M	130.2M
Accumulated Other Comprehensive Income	17.4M	(1.5M)	(376K)	41.3M	29.9M	16.4M
Short Term Debt	52.3M	53.6M	28.3M	20.3M	19.6M	22.7M
Intangible Assets	173.4M	156.5M	350.3M	338.8M	290.0M	149.3M
Non Current Liabilities Total	39.4M	39.4M	44.6M	87.7M	84.6M	88.8M

Pair Trading with Knight Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Knight Stock

0.69	TD-PFI	Toronto Dominion Bank	Pair Corr
0.66	FTN-PA	Financial 15 Split	Pair Corr
0.64	NVDA	NVIDIA CDR	Pair Corr
0.63	FFH	Fairfax Financial	Pair Corr
0.57	FSV	FirstService Corp	Pair Corr

The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.

The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Knight Stock

Balance Sheet is a snapshot of the financial position of Knight Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Knight Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Knight Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Knight currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Knight Days Sales Outstanding vs Pb Ratio Analysis

Days Sales Outstanding vs Pb Ratio

Days Sales Outstanding vs Pb Ratio Correlation Analysis

Correlation Coefficient

Days Sales Outstanding

Pb Ratio

Knight Therapeutics fundamental ratios Correlations

Knight Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Knight Therapeutics fundamental ratios Accounts

Pair Trading with Knight Therapeutics

Moving against Knight Stock

Other Information on Investing in Knight Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 0.99	Total Stockholder Equity
Inventory	+ 0.99	Accounts Payable
Common Stock	+ 0.98	Total Assets
Total Liab	+ 0.98	Total Current Liabilities
Other Current Assets	+ 0.97	Other Current Liab
Non Current Liabilities Total	+ 0.97	Accounts Payable

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.93	Net Debt
Total Current Assets	- 0.73	Net Debt
Retained Earnings	- 0.64	Other Current Liab
Short Term Investments	- 0.62	Net Debt
Other Current Assets	- 0.61	Retained Earnings